ClinicalTrials.gg
Status unknownNCT05598268Updated Oct 28, 2022

A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors.

A Phase 1/2 interventional study of T3011 in Advanced Solid Tumor, Lung Cancer and Liver Cancer, sponsored by ImmVira Pharma Co. Ltd. Status unknown at 7 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-28.

Primary conditionnone(registry's first term: Lung Neoplasms)Many cancersIs this wrong?The study is open to many cancers (its listed conditions name solid tumors in general), and its title does not single out Lung Neoplasms, so we do not take that as its main condition. It is not compared with other studies by condition.

Sponsored by ImmVira Pharma Co. Ltd · Phase 1/2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Oct 2022), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Mar 2022, registered Oct 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
74
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a multicenter, open-label study conducted in 3 phases:

Dose escalation stage: The stage contain 4 cohorts, each cohort divided into 2 groups (group A, single dose and Group B, multiple dose).Dose escalation will use a 3+3 design to evaluate escalating doses of T3011.Cohorts of three subjects will be enrolled at each T3011 dose level with expansion to six subjects, if necessary, to assess toxicity. Total enrollment will depend on the toxicities observed, with approximately 4-24 evaluable subjects enrolled in dose escalation stage.

Dose extension stage: The SMC will evaluate the available safety and preliminary efficacy data and initiate dose-expansion studies for the appropriate indications Phase IIa: To explore the safety of intravenous administration and expand the study in other indications. the stage will be carried out gradually based on the data obtained from the phase I study.

Read the detailed description

This is a multicenter, open-label study conducted in 3 phases:

Dose escalation stage: The stage contains 4 cohorts, divided into cohort 1 (1x106PFU/ dose), cohort 2 (1x107PFU/ dose), cohort 3 (1x108PFU/ dose) and cohort 4 (3x108PFU/ dose). Each cohort divided into 2 groups (group A, single dose and Group B, multiple dose).Dose escalation will use a 3+3 design to evaluate escalating doses of T3011. At any dose level, if no DLT occurs among the first 3 subjects, then escalation to the next dose level may proceed, with the approval of the SMC. If 1 DLT occurs in the first 1 to 3 subjects, the dose level will expand to a maximum of 6 subjects. If no DLT occurs among the additional subjects, then escalation to the next dose level may proceed, with the approval of the SMC. If 2 or more DLTs occur within a cohort, then that dose level will be above the maximum tolerated dose (MTD) (the highest dose where no more than 1 of 6 subjects has experienced a DLT), and new subjects will be enrolled at the previous lower (tolerated) dose level until that cohort has 6 subjects. This lower dose level will be considered the MTD if ≤ 1 in 6 subjects has a DLT. At the end of dose escalation, the SMC will recommend a dose (the recommended phase 2 dose [RP2D]) of T3011 to be used in phase 2a expansion study based upon MTD identification, cumulative safety, pharmacokinetic (PK), efficacy, and pharmacodynamic data. Total enrollment will depend on the toxicities observed, with approximately 4-24 evaluable subjects enrolled in dose escalation stage.

In group A, participant will receive a single dose and the DLT evaluation period is 14 days.

In group B, Participants will receive administration at D1/D4/D8 of every cycle. The DLT evaluation period will be the first 21-day Cycle in group B. Tumor evaluation was performed every two cycles. The maximum treatment period should not exceed 4 cycles. Group B of cohort X was enrolled only after the DLT assessed for group A of cohort X and SMC approval to proceed to the next cohort assessment.

Dose extension stage: The SMC will evaluate the available safety and preliminary efficacy data and initiate dose-expansion studies for the appropriate indications Phase IIa: To explore the safety of intravenous administration and expand the study in other indications. the stage will be carried out gradually based on the data obtained from the phase I study.

02

Conditions studied

  • Advanced Solid Tumor
  • Lung Cancer
  • Liver Cancer
  • Lymphoma
  • Mesothelioma of Pleura

Browse trials for

Keywords

  • Herpes virus
  • Advanced solid tumor
  • Dose escalation
  • T3011
  • Oncolytic virus
03

In context

Lead sponsor

ImmVira Pharma Co. Ltd is the lead sponsor of 8 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Locally recurrent or solid tumors, There is currently no effective treatment (including treatment intolerance).

      1. Age 18 years or older. 3. At least one target lesion per version 1.1. 4. (ECOG) performance status 0 - 1. 5. ≥ 12 weeks. 6. Women of must have a negative serum pregnancy test at Screening within 7 days of dosing with T3011.
      1. Understand and sign ICF voluntarily,capable of understanding and complying with protocol requirements.

Exclusion criteria

Exclusion Criteria:

    1. Pregnant or lactating or plan to pregnant or give birth during the trial. 2. Splenectomy, previous allogenic organ transplant. 3. Prior treatment with another gene therapy(except T3011). 4. Requires continued concurrent systemic therapy with any drug active against HSV (acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir, foscarnet, cidofovir). Topical use of drugs against HSV are allowed.

      1. History of allergic reactions attributed to compounds of similar biological composition to HSV-1, IL-12, or monoclonal antibody or their .
      1. Prior treatment with anti-PD-(L)1 monoclonal antibody in combination with IL-12.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
74 participants (estimated)

Study arms

  • Experimental
    T3011 Herpes Virus Injection

    Biological: T3011

Interventions

06

What researchers measure

Primary outcomes

  1. Evaluate the safety and tolerability of escalating doses of IV T3011 in Patients with advanced malignant tumors

    Incidence of AE(TEAE)

    Time frame: Up to 2 years from first dose of T3011

  2. Assess DLTs and identify the RP2D of single agent IV T3011

    Incidence of DLT

    Time frame: Up to 2 years from first dose of T3011

  3. Assess safety and tolerability of T3011 intravenous administration at MTD or RP2D doses through dose extension study

    Incidence of AE(TEAE)

    Time frame: Up to 2 years from first dose of T3011

Secondary outcomes

  1. Evaluate the biodistribution and viral shedding of IV T3011

    Measurement of T3011 in subjects' blood, urine, and saliva for biodistribution and viral shedding

    Time frame: Up to 2 years from first dose of T3011

  2. Evaluate the immunogenicity of IV T3011

    Measurement of ADAs and Nabs of IL-12, anti-PD-1 antibody and HSV-1 (test Nabs when ADAs are positive).

    Time frame: Up to 2 years from first dose of T3011

  3. Evaluate the preliminary clinical response of single agent IV T3011

    ORR PFS and OS

    Time frame: Up to 2 years from first dose of T3011

Other outcomes

  1. Exploring tumor immunomodulatory mechanism

    Lymphocyte typing

    Time frame: Up to 42 days from first dose of T3011

  2. Exploring histological changes after IT T3011

    Immunofluorescence detection

    Time frame: Up to 42 days from first dose of T3011

  3. Exploring the relationship between genetic changes and drug efficacy

    Tumor tissue sequencing

    Time frame: Up to 42 days from first dose of T3011

07

Study locations

7 of 7 sites recruiting
  • The First Affiliated Hospital of Bengbu Medicial College
    Bengbu, Anhui 233099, China
    Recruiting
  • Zhujiang Hospital of Southern Medical University
    Guanzhou, Guangdong 510280, China
    Recruiting
  • the First Affiliated Hospital of Henan University of Science and Technology
    Luoyang, Henan 450052, China
    Recruiting
  • Henan Cancer Hosptial
    Zhengzhou, Henan 450003, China
    Recruiting
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610044, China
    Recruiting
  • Beijing Chest Hospital
    Beijing, 101149, China
    Recruiting
  • Shanghai Chest Hosptial
    Shanghai, 200030, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2022 (actual). Primary completion is estimated for Jun 2024, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2022
First posted
Oct 28, 2022
StartActual
Mar 1, 2022
Primary completionEst.
Jun 2024
CompletionEst.
Dec 2024
Last update
Oct 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05598268
Lead sponsor
ImmVira Pharma Co. Ltd
Responsible party
Sponsor
First posted
Oct 28, 2022
Start date
Mar 1, 2022
Primary completion
Jun 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Oct 28, 2022

Study contacts

ImmVira Pharma Co. LTD
Contact
clinicaltrials@immviragroup.com
781-718-5121

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011

Start the discussion